Oslo, Norway, September 9, 2026 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced that its CEO, Michael
Engsig, and CSO and Co-founder, Agnete Fredriksen, will participate in the H.C.
Wainwright 28th Annual Global Investment Conference, taking place September
14-16, 2026, in New York, where they will present and host one-on-one meetings
with investors.
Presentation Details:
Event: H.C. Wainwright 28th Annual Global Investment Conference
Date: Wednesday, September 16, 2026
Time: 11:30 a.m. ET / 5:30 p.m. CEST
Location: Lotte New York Palace, New York City
Room: Holmes II - 4th Floor
During the conference, management will discuss Nykode's recent progress and key
value drivers, including its lead program, abi-suva, currently being evaluated
in the randomized Phase 2 Abili-T trial in first-line head and neck cancer;
VB10.NEO, an individualized neoantigen immunotherapy designed to generate
personalized, tumor-specific immune responses; and its immune tolerance
platform.
Investors interested in scheduling a one-on-one meeting with Nykode management
should contact their H.C. Wainwright representative.
The presentation slides will be available in the Investors section of the
Company's website at https://nykode.com/investors/events-presentations/
About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies with a focus on the
treatment of cancer and autoimmune diseases. Nykode's modular immunotherapy
technology specifically targets antigens to antigen presenting cells (APC),
which have been shown to induce a broad, strong and long-lasting antigen
specific immune response in cancer, which correlates with clinical responses.
Nykode's lead product candidates are abi-suva, a therapeutic immunotherapy for
the treatment of HPV16 induced malignancies which demonstrated favorable safety
and efficacy results from its Phase 2 trial for the treatment of late-line r/m
cervical cancer. Abi-suva is currently being further developed in first line
head and neck cancer with the randomized Abili-T trial with interim results
within 2027. VB10.NEO, an individualized cancer neoantigen immunotherapy, has
been investigated in two trials with more than 10 different indications.
Nykode is also utilizing its APC-targeted technology to create an immune
tolerance platform for the potential use in autoimmune disorders, organ
transplant rejections, anti-drug antibody reactions and allergy.
Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD).
Further information about Nykode Therapeutics can be found at
http://www.nykode.com.
Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by these forward-looking statements.
Contact for Nykode Therapeutics ASA:
IR@nykode.com
Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway
ASA:\
IR@nykode.com\
\
Nykode Therapeutics ASA\
Oslo Science Park\
Gaustadalléen 21\
N-0349 Oslo\, Norway\